Gene Therapy Competitive Landscape Assessment, 2023 Updates | In-depth Insights into the Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Clinical Trials, and Treatment Outlook | Key Companies - Nervosave Therapeutics, Vivet Therapeutics, Homology Med

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Gene Therapy Competitive Landscape constitutes key companies continuously working towards developing Gene Therapy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Gene Therapy Competitive Landscape Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Gene Therapy Market.

The Gene Therapy Competitive Landscape report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Gene Therapy Competitive Landscape Report: https://www.delveinsight.com/report-store/gene-therapy-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Gene Therapy treatment therapies with a considerable amount of success over the years.
• Gene Therapy companies working in the treatment market are Nervosave Therapeutics, Vivet Therapeutics, Homology Medicines, Duet Therapeutics, Rocket Pharmaceuticals, Nanoscope Therapeutics, Gyroscope Therapeutics, Adverum Biotechnologies, Dimension Therapeutics, Pfizer, HELIXMITH Co, Novartis, Spark Therapeutics, and others, are developing therapies for the Gene Therapy treatment
• Emerging Gene Therapy therapies such as - NVO-101, VTX-802, HMI 103, DUET-01, RP-L102, MCO 010, GT005, ADVM-022, DTX401, Fordadistrogene movaparvovec, Engensis, Zolgensma, Voretigeneneparvovec, and others are expected to have a significant impact on the Gene Therapy market in the coming years.
• In April 2022, The Durham, North Carolina, site, a multi-product gene therapy manufacturing facility, received commercial licence permission from the US Food and Drug Administration (FDA), according to a Novartis announcement. This authorization enables the cutting-edge, 170,000 square foot facility to manufacture, test, and commercialise Zolgensma as well as gene therapy products for ongoing and upcoming clinical trials
• In May 2019, The first gene therapy authorised to treat infants younger than two years of age with spinal muscular atrophy (SMA), the most severe type of SMA and a major genetic cause of infant mortality, was Zolgensma (onasemnogene abeparvovec-xioi), according to the US Food and Drug Administration

Gene Therapy Overview
The term "gene therapy" refers to the process of treating disease by introducing genetic material into cells. The ability to improve genes through the correction of misplaced (mutated) genes or site-specific alterations with therapeutic treatment as the target is known as gene therapy.

Get a Free Sample PDF Report to know more about Gene Therapy Competitive Landscape Therapeutic Assessment-
https://www.delveinsight.com/sample-request/gene-therapy-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Gene Therapy Drugs Under Different Phases of Clinical Development Include:
• NVO-101: Nervosave Therapeutics
• VTX-802: Vivet Therapeutics
• HMI 103: Homology Medicines
• DUET-01: Duet Therapeutics
• RP-L102: Rocket Pharmaceuticals
• MCO 010: Nanoscope Therapeutics
• GT005: Gyroscope Therapeutics
• ADVM-022: Adverum Biotechnologies
• DTX401: Dimension Therapeutics
• Fordadistrogene movaparvovec: Pfizer
• Engensis: HELIXMITH Co
• Zolgensma: Novartis
• Voretigeneneparvovec: Spark Therapeutics

Gene Therapy Competitive Landscape Therapeutics Assessment
• Gene Therapy Assessment by Product Type
• Gene Therapy By Stage and Product Type
• Gene Therapy Assessment by Route of Administration
• Gene Therapy By Stage and Route of Administration
• Gene Therapy Assessment by Molecule Type
• Gene Therapy by Stage and Molecule Type

DelveInsight's Gene Therapy Report covers around products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Gene Therapy product details are provided in the report. Download the Gene Therapy Competitive Landscape report to learn more about the emerging Gene Therapy therapies at:
https://www.delveinsight.com/sample-request/gene-therapy-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Gene Therapy Therapeutics Market include:
Key companies developing therapies for Gene Therapy are - Novartis, Bluebird Bio, Spark Therapeutics (a Roche company), Pfizer, Biogen, Sangamo Therapeutics, UniQure, Orchard Therapeutics (a Roche company), CRISPR Therapeutics, Editas Medicine, Regenxbio, Intellia Therapeutics, AveXis (a Novartis company), GenSight Biologics, Sarepta Therapeutics, Dimension Therapeutics (a Regenxbio company), MeiraGTx, Rocket Pharmaceuticals, Adverum Biotechnologies, Akouos, and others.

Gene Therapy Competitive Landscape Analysis:
The Gene Therapy Competitive Landscape report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Gene Therapy with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Gene Therapy Treatment.
• Gene Therapy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Gene Therapy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Gene Therapy market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Gene Therapy drugs and therapies-
https://www.delveinsight.com/sample-request/gene-therapy-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Gene Therapy Competitive Landscape Market Drivers
• Surge in research and development activities to develop gene therapies, technological advancements in genomic research are some of the important factors that are fueling the Gene Therapy Market.

Gene Therapy Competitive Landscape Market Barriers
• However, high cost of gene therapies, lack of relevant procedures and aftercare and other factors are creating obstacles in the Gene Therapy Market growth.

Scope of Gene Therapy Competitive Landscape Drug Insight
• Coverage: Global
• Key Gene Therapy Companies: Nervosave Therapeutics, Vivet Therapeutics, Homology Medicines, Duet Therapeutics, Rocket Pharmaceuticals, Nanoscope Therapeutics, Gyroscope Therapeutics, Adverum Biotechnologies, Dimension Therapeutics, Pfizer, HELIXMITH Co, Novartis, Spark Therapeutics, and others
• Key Gene Therapy Therapies: NVO-101, VTX-802, HMI 103, DUET-01, RP-L102, MCO 010, GT005, ADVM-022, DTX401, Fordadistrogene movaparvovec, Engensis, Zolgensma, Voretigeneneparvovec, and others
• Gene Therapy Therapeutic Assessment: Gene Therapy current marketed and Gene Therapy emerging therapies
• Gene Therapy Market Dynamics: Gene Therapy market drivers and Gene Therapy market barriers

Request for Sample PDF Report for Gene Therapy Competitive Landscape Assessment and clinical trials-
https://www.delveinsight.com/sample-request/gene-therapy-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1 Gene Therapy Report Introduction
2 Gene Therapy Executive Summary
3 Gene Therapy Overview
4 Gene Therapy- Analytical Perspective In-depth Commercial Assessment
5 Gene Therapy Competitive Landscape Therapeutics
6 Gene Therapy Late Stage Products (Phase II/III)
7 Gene Therapy Mid Stage Products (Phase II)
8 Gene Therapy Early Stage Products (Phase I)
9 Gene Therapy Preclinical Stage Products
10 Gene Therapy Therapeutics Assessment
11 Gene Therapy Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Gene Therapy Key Companies
14 Gene Therapy Key Products
15 Gene Therapy Unmet Needs
16 Gene Therapy Market Drivers and Barriers
17 Gene Therapy Future Perspectives and Conclusion
18 Gene Therapy Analyst Views
19 Appendix
20 About DelveInsight
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Latest Reports:
Scedosporium Infection Market https://www.delveinsight.com/report-store/scedosporium-infection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Scedosporium Infection Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Scedosporium Infection, historical and forecasted epidemiology as well as the Scedosporium Infection market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Vascular Graft Devices Market https://www.delveinsight.com/report-store/vascular-grafts-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Vascular Graft Devices Market By Product Type (Endovascular Grafts [Abdominal And Thoracic], Access Grafts, Peripheral Grafts, And Others), By Type (Knitted, Woven, And Others), By Material (Synthetic[ Polytetrafluoroethylene [PTFE], Polyester, Polyurethane], Biological, And Others), By End User (Hospitals, Ambulatory Surgical Centers, And Others), by geography is expected to register commendable revenue growth at a steady CAGR forecast till 2027 owing to increasing prevalence of cardiovascular diseases such as aortic aneurysms and peripheral artery disease and growing patient for kidney dialysis.

Vascular Stents Market https://www.delveinsight.com/report-store/vascular-stents-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Vascular Stents Market By Product Type (Coronary Stents, Peripheral Stents [Carotid Stents, Iliac Stents, Femoral Stents, Femoral Stents, Other], Evar Stent Grafts [Abdominal Aortic Aneurysm Stents, Thoracic Aortic Aneurysm Stents]), By Type (Bare-Metal Stents, Drug-Eluting Stents), By Material (Metal And Polymer), By Mode Of Delivery (Balloon-Expandable Stents And Self Expandable Stents), By End-User (Hospitals And Ambulatory Surgical Centers), by geography, is expected to grow at a noteworthy CAGR forecast till 2027 owing to rising burden of vascular diseases across the globe and increasing preferences of minimally invasive surgeries among the patient population.

Vein Illumination Devices Market https://www.delveinsight.com/report-store/vein-illumination-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Vein Illumination Devices Market Insight, Competitive Landscape and Market Forecast, 2027" report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Bladder Scanners Market https://www.delveinsight.com/report-store/bladder-scanners-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Bladder Scanners Market Insight, Competitive Landscape and Market Forecast, 2027" report delivers an in-depth understanding of Bladder Scanners and the historical and forecasted Bladder Scanners market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Recent Blog's By DelveInsight:

• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr

Contact Us:

Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
Healthcare Consulting

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.